Table 1.
Demographic characteristics and details at baseline
| Characteristics | Placebo (n = 27) | BTX-A (25u) (n = 25) | BTX-A (75u) (n = 28) | Total (n = 80) | P value | |
|---|---|---|---|---|---|---|
| Age, mean (SD), y |
Mean (SD) |
58.41 (11.74) |
58.16 (11.54) |
62.64 (13.32) |
59.81 (12.30) |
0.363 |
| |
Median |
60 |
59 |
63 |
60 |
|
| |
Min/max |
31/78 |
41/80 |
40/89 |
31/89 |
|
| Mean months since onset of TN |
Mean (SD) |
50.96 (46.26) |
91.96 (72.61) |
72.64 (76.45) |
71.36 (67.68) |
0.181 |
| |
Median |
36 |
96 |
36 |
48 |
|
| |
Min/max |
4/210 |
4/300 |
4/270 |
4/300 |
|
| Sex |
Male |
51.85% |
40% |
42.86% |
45% |
0.665 |
| Pain intensity,VAS |
Mean (SD) |
6.96 (1.97) |
6.24 (2.13) |
7.18 (2.21) |
6.81 (2.12) |
0.197 |
| |
Median |
7 |
5 |
6.5 |
6 |
|
| Min/max | 4/10 | 4/10 | 4/10 | 4/10 |